Latest Conference Articles

Yesintek Biosimilar Shows Comparable Efficacy, Lower Immunogenicity Than Stelara, Says Elena Wolff-Holz, MD

Cameron Santoro,Elena Wolff-Holz, MD

May 11 2025

Elena Wolff-Holz, MD, discussed the approval and benefits of the ustekinumab biosimilar, Yesintek, emphasizing its comparable efficacy and safety to Stelara, and potential for increased patient access due to lower costs, and a possible lower immunogenicity profile.

Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow

Cameron Santoro

May 6 2025

Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.

Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships

Skylar Jeremias

April 29 2025

Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.

FDA's Expanded Access: From Laetrile to Right to Try, Ethical Debates Over Early Drug Access

Cameron Santoro

April 28 2025

Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.

Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market

Cameron Santoro

April 25 2025

Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.

Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes

Cameron Santoro

April 24 2025

Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.

Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain

Cameron Santoro

April 24 2025

Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.

Early Success of Adalimumab Biosimilars Featured at AMCP 2025

Skylar Jeremias

April 5 2025

High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).

Promising Results for Ustekinumab, Adalimumab Biosimilars Presented at AAD

Skylar Jeremias

March 18 2025

Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved interchangeable with reference adalimumab, according to posters at the American Academy of Dermatology (AAD) annual meeting.

The Top 5 Most-Read Conference Articles of 2024

Skylar Jeremias

December 26 2024

The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including strategies for market sustainability, safety of switching to biosimilars, and substantial savings through high biosimilar adoption, while also addressing ongoing challenges.